Skeletal metastasis: Treatments, mouse models, and the Wnt signaling

Chinese Journal of Cancer

Volumn 32, Issue 7, 2013, Pages 380-396

  Valkenburg, Kenneth C ^a   Steensma, Matthew R ^a,b   Williams, Bart O ^a   Zhong, Zhendong ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b Orthopedic Oncology   (United States)

Author keywords

Cancer; Mouse models; Skeletal metastasis; Therapy; Wnt signaling

Indexed keywords

ABIRATERONE ACETATE; ALENDRONIC ACID; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; CABOZANTINIB; DENOSUMAB; ETIDRONIC ACID; GONADORELIN AGONIST; IBANDRONIC ACID; KI 26894; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; ODANACATIB; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RECLASE; RISEDRONIC ACID; SCATTER FACTOR RECEPTOR; SEOCALCITOL; TAMOXIFEN; TAMOXIFEN CITRATE; TILUDRONIC ACID; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; WNT PROTEIN; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG APPROVAL; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMMUNE DEFICIENCY; LUNG CANCER; MOUSE; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOLYSIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; BETA CATENIN; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; PROSTATIC NEOPLASMS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84879807719     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10218     Document Type: Review

References (216)

1. Cancer facts & figures. Atlanta: American Cancer Society, Inc, 2011.
2. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer, 2006,106:1624-1633.
3. Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in spain. Eur J Cancer Care (Engl), 2010,19:755-760.
4. Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med, 2011,17:1235-1241.
5. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer, 2009,9:274-284.
6. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet, 2007,8:341-352.
7. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med, 2008,359:2814-2823.
8. Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889,1:571-573.
9. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer, 2002,2:584-593.
10. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003,3:537-549.
11. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol, 2011,8:357-368.
12. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer, 2000,88:2919-2926.
13. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001,410:50-56.
14. Sun YX, Fang M, Wang J, et al. Expression and activation of alpha v beta 3 integrins by sdf-1/cxc12 increases the aggressiveness of prostate cancer cells. Prostate, 2007,67:61-73.
15. Pauli BU, Augustin-Voss HG, el-Sabban ME, et al. Organpreference of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Rev, 1990,9:175-189.
16. Kelly T, Suva LJ, Huang Y, et al. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res, 2005,65:5778-5784.
17. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell, 2008,133:994-1005.
18. Lynch CC, Hikosaka A, Acuff HB, et al. Mmp-7 promotes prostate cancer-induced osteolysis via the solubilization of rankl. Cancer Cell, 2005,7:485-496.
19. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer, 2011,11:411-425.
20. Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest, 2011,121:1298-1312.
21. Norgaard M, Jensen AO, Jacobsen JB, et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in denmark (1999 to 2007). J Urol, 2010,184:162-167.
22. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol, 2000,31:578-583.
23. Jensen AO, Jacobsen JB, Norgaard M, et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in denmark. BMC Cancer, 2011,11:29.
24. Stenbygaard LE, Sorensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung- a study from a cohort of 259 consecutive patients treated with chemotherapy. Acta Oncol, 1997,36:301-306.
25. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol, 1983,23:175-180.
26. Steensma M, Boland PJ, Morris CD, et al. Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res, 2012,470:920-926.
27. Aboulafia AJ, Levine AM, Schmidt D, et al. Surgical therapy of bone metastases. Semin Oncol, 2007,34:206-214.
28. Hansen BH, Keller J, Laitinen M, et al. The scandinavian sarcoma group skeletal metastasis register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl, 2004,75:11-15.
29. Luketich JD, Martini N, Ginsberg RJ, et al. Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann Thorac Surg, 1995,60:1609-1611.
30. Wedin R, Falkenius J, Weiss RJ, et al. Surgical treatment of skeletal metastases in 31 melanoma patients. Acta Orthop Belg, 2012,78:246-253.
31. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am, 2007,89:1794-1801.
32. Martini N, Huvos AG, Burt ME, et al. Predictors of survival in malignant tumors of the sternum. J Thorac Cardiovasc Surg, 1996,111:96-105; discussion 105-106.
33. Feyer PC, Steingraeber M. Radiotherapy of bone metastasis in breast cancer patients-current approaches. Breast Care (Basel), 2012,7:108-112.
34. Vakaet LA, Boterberg T. Pain control by ionizing radiation of bone metastasis. Int J Dev Biol, 2004,48:599-606.
35. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys, 1995,32:959-967.
36. Yamada Y. Treating spinal bone metastasis with image-guided, high-dose radiation. Varian Medical Systems, 2008:1-4.
37. Koyfman SA, Djemil T, Burdick MJ, et al. Marginal recurrence requiring salvage radiotherapy after stereotactic body radio-therapy for spinal metastases. Int J Radiat Oncol Biol Phys, 2012,83:297-302.
38. Cheetham PJ, Petrylak DP. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: Mechanism of action of radium-223 chloride (alpharadin) and radiation protection. Oncology (Williston Park), 2012,26:330-337, 341.
39. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2009,7:122-192.
40. Sternberg CN. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol, 2008,19 Suppl 7:vii91-95.
41. Loriot Y, Massard C, Fizazi K. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol, 2012,23:1085-1094.
42. Makarov DV, Humphreys EB, Mangold LA, et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol, 2008,179:156-161; discussion 161-152.
43. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/c(17,20)-lyase inhibitor abiraterone acetate (cb7630) in patients with prostate cancer. Br J Cancer, 2004,90:2317-2325.
44. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 2011,364:1995-2005.
45. Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol, 2012,30:637-643.
46. Corey E, Quinn JE, Vessella RL. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate, 2003,56:110-114.
47. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab, 2010,95:3569-3577.
48. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med, 2005,352:154-164.
49. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol, 2005,23:7897-7903.
50. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/rankl/rank system for bone and vascular diseases. JAMA, 2004,292:490-495.
51. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the nsabp Study of Tamoxifen and Raloxifene (star) P-2 trial. JAMA, 2006,295:2727-2741.
52. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmeno pausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst, 2004,96:1751-1761.
53. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of gtp-binding proteins, including Ras. J Bone Miner Res, 1998,13:581-589.
54. Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw, 2009,7 Suppl 7:S1-29; quiz S30.
55. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc, 2008,83:1032-1045.
56. Asahi H, Mizokami A, Miwa S, et al. Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int J Urol, 2006,13:593-600.
57. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res, 2003,9:2394-2399.
58. Puhaindran ME, Farooki A, Steensma MR, et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am, 2011,93:1235-1242.
59. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther, 2003,25:2669-2708.
60. Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med, 2012,18:456-462.
61. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of amg 162, a fully human monoclonal antibody to rankl, in postmenopausal women. J Bone Miner Res, 2004,19:1059-1066.
62. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011,377:813-822.
63. Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine n-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase ii trial. J Urol, 2009,182:509-515; discussion 515-506.
64. Xie J, Namjoshi M, Wu EQ, et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm, 2011,17:621-643.
65. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med, 2008,358:1304-1306.
66. Mechcatie E. Fda panel rejects denosumab against bone metastasis in prostate cancer. Internal Medicine News, 2012. Available at: http://www.internalmedicinenews.com/single-view/fda-panel-rejects-denosumab-against-bone-metastasis-inprostate-cancer/839e175a56.html
67. Armstrong AP, Miller RE, Jones JC, et al. Rankl acts directly on rank-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate, 2008,68:92-104.
68. Canon JR, Roudier M, Bryant R, et al. Inhibition of rankl blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis, 2008,25:119-129.
69. Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res, 2003,63:7883-7890.
70. Canon J, Bryant R, Roudier M, et al. Inhibition of rankl increases the anti-tumor effect of the egfr inhibitor panitumumab in a murine model of bone metastasis. Bone, 2010,46: 1613-1619.
71. Holland PM, Miller R, Jones J, et al. Combined therapy with the rankl inhibitor rank-fc and rhapo2l/trail/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther, 2010,9:539-550.
72. Le Gall C, Bellahcene A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res, 2007,67:9894-9902.
73. Peroni A, Zini A, Braga V, et al. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol, 2008,59:125-129.
74. Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer, 2010,10:452-458.
75. Withana NP, Blum G, Sameni M, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res, 2012,72:1199-1209.
76. Liao J, Li X, Koh AJ, et al. Tumor expressed pthrp facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer, 2008,123:2267-2278.
77. Bhatia V, Saini MK, Shen X, et al. Eb1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther, 2009,8:1787-1798.
78. Alonso V, de Gortazar AR, Ardura JA, et al. Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol, 2008,217:717-727.
79. Li J, Karaplis AC, Huang DC, et al. Pthrp drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest, 2011,121:4655-4669.
80. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest, 1996,98:1544-1549.
81. Iguchi H, Tanaka S, Ozawa Y, et al. An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res, 1996,56:4040-4043.
82. Saito H, Tsunenari T, Onuma E, et al. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from mda-mb-231. Anticancer Res, 2005,25:3817-3823.
83. Coleman RE, Lipton A, Roodman GD, et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev, 2010,36:615-620.
84. Javelaud D, Alexaki VI, Dennler S, et al. Tgf-beta/smad/gli2 signaling axis in cancer progression and metastasis. Cancer Res, 2011,71:5606-5610.
85. Bismar H, Kloppinger T, Schuster EM, et al. Transforming growth factor beta (tgf-beta) levels in the conditioned media of human bone cells: relationship to donor age, bone volume, and concentration of tgf-beta in human bone matrix in vivo. Bone, 1999,24:565-569.
86. Seyedin SM, Thomas TC, Thompson AY, et al. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci U S A, 1985,82:2267-2271.
87. Tang Y, Wu X, Lei W, et al. Tgf-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med, 2009,15:757-765.
88. Janssens K, ten Dijke P, Janssens S, et al. Transforming growth factor-beta1 to the bone. Endocr Rev, 2005,26:743-774.
89. Zavadil J, Bottinger EP. Tgf-beta and epithelial-to-mesenchymal transitions. Oncogene, 2005,24:5764-5774.
90. Ehata S, Hanyu A, Fujime M, et al. Ki26894, a novel transforming growth factor-beta type i receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci, 2007,98:127-133.
91. Yin JJ, Selander K, Chirgwin JM, et al. Tgf-beta signaling blockade inhibits pthrp secretion by breast cancer cells and bone metastases development. J Clin Invest, 1999,103:197-206.
92. Reis ST, Pontes-Junior J, Antunes AA, et al. Tgf-beta1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo), 2011,66:1143-1147.
93. Wan X, Li ZG, Yingling JM, et al. Effect of transforming growth factor beta (tgf-beta) receptor i kinase inhibitor on prostate cancer bone growth. Bone, 2012,50:695-703.
94. Hu Z, Gupta J, Zhang Z, et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther, 2012,23:871-882.
95. Yakes FM, Chen J, Tan J, et al. Cabozantinib (xl184), a novel met and vegfr2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011,10:2298-2308.
96. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-met and vegf signaling in pancreatic neuroendocrine tumors. Cancer Discov, 2012,2:270-287.
97. Laino C. Prostate cancer: promising results with cabozantinibg, abiraterone, and degarelix. Oncology Times, 2011,8:9-10.
98. Hussein O, Tiedemann K, Murshed M, et al. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett, 2012,314:176-184.
99. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther, 2006,318:161-172.
100. Barton S, Swanton C. Recent developments in treatment stratification for metastatic breast cancer. Drugs, 2011,71:2099-2113.
101. Onishi T, Hayashi N, Theriault RL, et al. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol, 2010,7:641-651.
102. Rove KO, Crawford ED. Evolution of treatment options for patients with crpc and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology (Williston Park), 2011, 25:1362-1370, 1375-1381, 1387.
103. Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in her2-positive metastatic breast cancer. Br J Cancer, 2012,106:6-13.
104. Robinson DR, Zylstra CR, Williams BO. Wnt signaling and prostate cancer. Curr Drug Targets, 2008,9:571-580.
105. Verras M, Sun Z. Roles and regulation of wnt signaling and betacatenin in prostate cancer. Cancer Lett, 2006,237:22-32.
106. Yardy GW, Brewster SF. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis, 2005,8:119-126.
107. Bruxvoort KJ, Charbonneau HM, Giambernardi TA, et al. Inactivation of apc in the mouse prostate causes prostate carcinoma. Cancer Res, 2007,67:2490-2496.
108. Yu X, Wang Y, DeGraff DJ, et al. Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene, 2011,30:1868-1879.
109. Bisson I, Prowse DM. Wnt signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res, 2009,19:683-697.
110. Chen G, Shukeir N, Potti A, et al. Up-regulation of wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer, 2004,101:1345-1356.
111. Gupta S, Iljin K, Sara H, et al. Fzd4 as a mediator of erg oncogene-induced wnt signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res, 2010,70:6735-6745.
112. Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through wnts. Cancer Res, 2005,65:7554-7560.
113. Hall CL, Daignault SD, Shah RB, et al. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate, 2008,68:1396-1404.
114. Uysal-Onganer P, Kawano Y, Caro M, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer, 2010,9:55.
115. Lindvall C, Zylstra CR, Evans N, et al. The wnt co-receptor lrp6 is required for normal mouse mammary gland development. PLoS One, 2009,4:e5813.
116. Vaillant F, Asselin-Labat ML, Shackleton M, et al. The mammary progenitor marker cd61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res, 2008,68:7711-7717.
117. Khramtsov AI, Khramtsova GF, Tretiakova M, et al. Wnt/ beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol, 2010,176:2911-2920.
118. Teissedre B, Pinderhughes A, Incassati A, et al. Mmtv-wnt1 and -deltan89beta-catenin induce canonical signaling in distinct progenitors and differentially activate hedgehog signaling within mammary tumors. PLoS One, 2009,4:e4537.
119. Tsukamoto AS, Grosschedl R, Guzman RC, et al. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell, 1988,55:619-625.
120. DiMeo TA, Anderson K, Phadke P, et al. A novel lung metastasis signature links wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res, 2009,69:5364-5373.
121. Klemm F, Bleckmann A, Siam L, et al. Beta-catenin-independent wnt signaling in basal-like breast cancer and brain metastasis. Carcinogenesis, 2011,32:434-442.
122. Valkenburg KC, Graveel CR, Zylstra-Diegel CR, et al. Wnt/beta-catenin signaling in normal and cancer stem cells. Cancers, 2011,3:2050-2079.
123. Nguyen DX, Chiang AC, Zhang XH, et al. Wnt/tcf signaling through lef1 and hoxb9 mediates lung adenocarcinoma metastasis. Cell, 2009,138:51-62.
124. Nakashima N, Liu D, Huang CL, et al. Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer, 2012,76:228-234.
125. Liu YL, Yang HP, Zhou XD, et al. The hypomethylation agent bisdemethoxycurcumin acts on the wif-1 promoter, inhibits the canonical wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets, 2011,11:1098-1110.
126. Pacheco-Pinedo EC, Durham AC, Stewart KM, et al. Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest,121:1935-1945.
127. Xi S, Yang M, Tao Y, et al. Cigarette smoke induces c/ebp-beta-mediated activation of mir-31 in normal human respiratory epithelia and lung cancer cells. PLoS One, 2010,5:e13764.
128. Goldring SR, Goldring MB. Eating bone or adding it: the wnt pathway decides. Nat Med, 2007,13:133-134.
129. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem, 2005,280:21162-21168.
130. Kramer I, Halleux C, Keller H, et al. Osteocyte wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol, 2010,30:3071-3085.
131. Cui Y, Niziolek PJ, MacDonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nat Med, 2011,17:684-691.
132. Holmen SL, Giambernardi TA, Zylstra CR, et al. Decreased bmd and limb deformities in mice carrying mutations in both lrp5 and lrp6. J Bone Miner Res, 2004,19:2033-2040.
133. Minear S, Leucht P, Jiang J, et al. Wnt proteins promote bone regeneration. Sci Transl Med, 2010,2:29ra30.
134. Yee DS, Tang Y, Li X, et al. The wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer, 2010,9:162.
135. Zhao JH, Luo Y, Jiang YG, et al. Knockdown of beta-catenin through shrna cause a reversal of emt and metastatic phenotypes induced by hif-1alpha. Cancer Invest, 2011,29:377-382.
136. Dai J, Hall CL, Escara-Wilke J, et al. Prostate cancer induces bone metastasis through wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res, 2008,68:5785-5794.
137. Thudi NK, Martin CK, Murahari S, et al. Dickkopf-1 (dkk-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate, 2011,71:615-625.
138. Li ZG, Yang J, Vazquez ES, et al. Low-density lipoprotein receptor-related protein 5 (lrp5) mediates the prostate cancer-induced formation of new bone. Oncogene, 2008,27:596-603.
139. Bu G, Lu W, Liu CC, et al. Breast cancer-derived dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer, 2008,123:1034-1042.
140. Voorzanger-Rousselot N, Goehrig D, Journe F, et al. Increased dickkopf-1 expression in breast cancer bone metastases. Br J Cancer, 2007,97:964-970.
141. Matsuda Y, Schlange T, Oakeley EJ, et al. Wnt signaling enhances breast cancer cell motility and blockade of the wnt pathway by sfrp1 suppresses mda-mb-231 xenograft growth. Breast Cancer Res, 2009,11:R32.
142. van der Velden JL, Guala AS, Leggett SE, et al. Induction of a mesenchymal expression program in lung epithelial cells by wnt/ beta-catenin requires the presence of c-jun n-terminal kinase 1. Am J Respir Cell Mol Biol, 2012,47:306-314.
143. You L, He B, Xu Z, et al. Inhibition of wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene, 2004,23:6170-6174.
144. Nusse R, Varmus H. Three decades of wnts: a personal perspective on how a scientific field developed. EMBO J, 2012,31:2670-2684.
145. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature, 2005,434:843-850.
146. Valkenburg KC, Williams BO. Mouse models of prostate cancer. Prostate Cancer, 2011,2011:1-22.
147. Neth P, Ciccarella M, Egea V, et al. Wnt signaling regulates the invasion capacity of human mesenchymal stem cells. Stem Cells, 2006,24:1892-1903.
148. Badders NM, Goel S, Clark RJ, et al. The wnt receptor, lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. PLoS One, 2009,4:e6594.
149. Teng Y, Wang X, Wang Y, et al. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer a549 cells. Biochem Biophys Res Commun, 2010,392:373-379.
150. Polakis P. The many ways of wnt in cancer. Curr Opin Genet Dev, 2007,17:45-51.
151. Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol, 2009,5:100-107.
152. van den Heuvel M, Harryman-Samos C, Klingensmith J, et al. Mutations in the segment polarity genes wingless and porcupine impair secretion of the wingless protein. EMBO J, 1993,12:5293-5302.
153. Fishman MC. Changing the practice of medicine. Novartis, 2010.
154. Barker N, Clevers H. Mining the wnt pathway for cancer therapeutics. Nat Rev Drug Discov, 2006,5:997-1014.
155. Moon RT, Kohn AD, De Ferrari GV, et al. Wnt and beta-catenin signalling: diseases and therapies. Nat Rev Genet, 2004,5:691-701.
156. Polakis P. Drugging wnt signalling in cancer. EMBO J, 2012,31:3375.
157. Fulciniti M, Tassone P, Hideshima T, et al. Anti-dkk1 mab (bhq880) as a potential therapeutic agent for multiple myeloma. Blood, 2009,114:371-379.
158. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of dkk1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 2007,109:2106-2111.
159. Zhou XL, Qin XR, Zhang XD, et al. Downregulation of dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of wnt/beta-catenin signaling. Acta Pharmacol Sin, 2010,31:202-210.
160. Borowsky AD. Choosing a mouse model: experimental biology in context-the utility and limitations of mouse models of breast cancer. Cold Spring Harb Perspect Biol, 2011,3:a009670.
161. Park SI, Kim SJ, McCauley LK, et al. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol, 2010,Chapter 14:Unit 14 15.
162. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res, 2003,9:5532-5539.
163. Howard RB, Mullen JB, Pagura ME, et al. Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat. Clin Exp Metastasis, 1999,17:157-162.
164. Chung LW, Hsieh CL, Law A, et al. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology, 2003,62:44-54.
165. Pettaway CA, Pathak S, Greene G, et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res, 1996,2:1627-1636.
166. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the lncap model of human prostate cancer. Cancer Res, 1994,54:2577-2581.
167. Thalmann GN, Sikes RA, Wu TT, et al. Lncap progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate, 2000,44:91-103.
168. Wu TT, Sikes RA, Cui Q, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and scid/bg mice using lncap and lineage-derived metastatic sublines. Int J Cancer, 1998,77:887-894.
169. Liepe K, Geidel H, Haase M, et al. New model for the induction of osteoblastic bone metastases in rat. Anticancer Res, 2005,25:1067-1073.
170. Nemeth JA, Harb JF, Barroso U Jr, et al. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res, 1999,59:1987-1993.
171. Yonou H, Yokose T, Kamijo T, et al. Establishment of a novel species-and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res, 2001,61:2177-2182.
172. Shtivelman E, Namikawa R. Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci U S A, 1995,92:4661-4665.
173. Tsingotjidou AS, Zotalis G, Jackson KR, et al. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res, 2001,21:971-978.
174. Bos PD, Nguyen DX, Massague J. Modeling metastasis in the mouse. Curr Opin Pharmacol, 2010,10:571-577.
175. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, et al. Animal models of bone metastasis. Cancer, 2003,97:748-757.
176. Singh AS, Figg WD. In vivo models of prostate cancer metastasis to bone. J Urol, 2005,174:820-826.
177. Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res, 2004,10:8147-8151.
178. Galsky MD, Dritselis A, Kirkpatrick P, et al. Cabazitaxel. Nat Rev Drug Discov, 2010,9:677-678.
179. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the egf104900 study. J Clin Oncol, 2012,31:2585-2592.
180. Paller CJ, Antonarakis E. Sipuleucel-t for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother, 2012,8:509-519.
181. Di Lauro V, Torrisi E, Bidoli E, et al. Trastuzumab and gemcitabine in pretreated her2 overexpressing metastatic breast cancer patients: retrospective analysis of our series. J Oncol, 2012,2012:198412.
182. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase iii study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the sparc trial. J Clin Oncol, 2009,27:5431-5438.
183. Dittrich C, Solska E, Manikhas A, et al. A phase ii multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer. Cancer Invest, 2012,30:309-316.
184. Hardy-Bessard AC, Delva R, Pivot X, et al. Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: Athena study-france. Bull Cancer, 2012,99:609-618.
185. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase ii trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment group and mayo clinic trial n0336. J Clin Oncol, 2009,27:11-15.
186. Castellano D, Gonzalez-Larriba JL, Anton-Aparicio LM, et al. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Expert Opin Pharmacother, 2011,12:2433-2439.
187. Miller RE, Roudier M, Jones J, et al. Rank ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther, 2008,7:2160-2169.
188. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res, 2003,63:287-289.
189. Curran MP. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs, 2012,72:99-107.
190. Dunlap N, Schwartz GG, Eads D, et al. 1alpha,25-dihydroxyvitamin d(3) (calcitriol) and its analogue, 19-nor-1alpha,25(oh)(2)d(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer, 2003,89:746-753.
191. Sundaram S, Sea A, Feldman S, et al. The combination of a potent vitamin d3 analog, eb 1089, with ionizing radiation reduces tumor growth and induces apoptosis of mcf-7 breast tumor xenografts in nude mice. Clin Cancer Res, 2003,9:2350-2356.
192. Jones MD, Liu JC, Barthel TK, et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res, 2010,16:4978-4989.
193. Qiang YW, Hu B, Chen Y, et al. Bortezomib induces osteoblast differentiation via wnt-independent activation of beta-catenin/ tcf signaling. Blood, 2009,113:4319-4330.
194. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase ii study. Lancet Oncol, 2007,8:587-594.
195. Yu EY, Miller K, Nelson J, et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase iii trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J Urol, 2012,188:103-109.
196. Palma JP, Wang YC, Rodriguez LE, et al. Abt-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res, 2009,15:7277-7290.
197. Bretschi M, Merz M, Komljenovic D, et al. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep, 2011,26:843-851.
198. Boffa DJ, Luan F, Thomas D, et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res, 2004,10:293-300.
199. Zhou H, Huang S. Mtor signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr, 2010,20:1-16.
200. Lynch CC. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone, 2011,48:44-53.
201. Lee J, Weber M, Mejia S, et al. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by mda-mb-231 human breast cancer cells in balb c nu/nu mice. Eur J Cancer, 2001,37:106-113.
202. Sung B, Oyajobi BO, Aggarwal BB. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of rankl signaling. Mol Cancer Ther, 2011,11:350-359.
203. Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (il)-6 in cancer metastasis to bone: potential of anti-il-6 therapies. Cancer Manag Res, 2011,3:177-189.
204. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer, 2010,46:1223-1231.
205. Chantry AD, Heath D, Mulivor AW, et al. Inhibiting activin-a signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res, 2010,25:2633-2646.
206. Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral gpiib/iiia antagonist xv454. Thromb Haemost, 2003,90:549-554.
207. Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest, 2004,114:1691-1693.
208. Rey JP, Ellies DL. Wnt modulators in the biotech pipeline. Dev Dyn, 2010,239:102-114.
209. Yeh JR, Peterson RT. Novel wnt antagonists target porcupine and axin. Nat Chem Biol, 2009,5:74-75.
210. Ettenberg SA, Charlat O, Daley MP, et al. Inhibition of tumorigenesis driven by different wnt proteins requires blockade of distinct ligand-binding regions by lrp6 antibodies. Proc Natl Acad Sci U S A.
211. Fitton A, McTavish D. Pamidronate. A review of its pharma-cological properties and therapeutic efficacy in resorptive bone disease. Drugs, 1991,41:289-318.
212. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone, 1995,17:383-390.
213. Khairi MR, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of paget's disease of bone. A study of long-term results. Ann Intern Med, 1977,87:656-663.
214. Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase ii studies. Clin Ther, 2003,25:19-34.
215. Goa KL, Balfour JA. Risedronate. Drugs Aging, 1998,13:83-91; discussion 92.
216. Murakami H, Takahashi N, Tanaka S, et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone, 1997,20:399-404.